Massachusetts dumps gift ban, punts on data

Share this article:
Massachusetts lawmakers trashed a proposed gift ban hotly contested by biotechs, a key industry in the state, and put off the effective date of a provision banning commercial use of prescriber data pending legal action on similar measures in other states.

The Boston Globe reported that the measure banning gifts was stripped from legislation approved by the House on Wednesday. The paper said lawmakers also pulled a measure requiring that drug and device companies report payments to physicians for consulting and speaking fees or face a $5,000 per violation fine.

Instead, the drug companies would be required to adopt “marketing code of conduct” similar to the PhRMA Code on Interactions with Healthcare Professionals, revisions to which were announced last week. The revised PhRMA code bans most gifts to physicians, along with meals out and “dine and dash” meals, calls for caps on speaker fees to individual physicians (to be determined by individual companies) and restricts some spending on CME events.

Still included in the Massachusetts legislation is a ban on commercial provision of prescriber data, but the measure would not take effect until November 2009. A consortium of health information firms–IMS Health, Verispan and Wolters Kluwer Health–have challenged similar policies elsewhere in New England, and lawmakers hoped to avoid a costly legal battle that might be resolved in other states.

Consumer groups said they would work to see that the gift ban included in the Senate version of the legislation prevails in conference.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...